Skip to main content
SpringerLink
Log in

5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia

  • Chapter
  • First Online:
Book cover Novel Antischizophrenia Treatments

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 213))

Abstract

The 5-HT2C receptor is a highly complex, highly regulated receptor which is widely distributed throughout the brain. The 5-HT2C receptor couples to multiple signal transduction pathways leading to engagement of a number of intracellular signaling molecules. Moreover, there are multiple allelic variants of the 5-HT2C receptor and the receptor is subject to RNA editing in the coding regions. The complexity of this receptor is further emphasized by the studies suggesting the utility of either agonists or antagonists in the treatment of schizophrenia. While several 5-HT2C agonists have demonstrated clinical efficacy in obesity (lorcaserin, PRX-000933), the focus of this review is on the therapeutic potential of 5-HT2C agonists in schizophrenia. To this end, the preclinical profile of 5-HT2C agonists from a neurochemical, electrophysiological, and a behavioral perspective is indicative of antipsychotic-like efficacy without extrapyramidal symptoms or weight gain. Recently, the selective 5-HT2C agonist vabicaserin demonstrated clinical efficacy in a Phase II trial in schizophrenia patients without weight gain and with low EPS liability. These data are highly encouraging and suggest that 5-HT2C agonists are potential therapeutics for the treatment of psychiatric disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine 2c receptor protein in human and rat brain using specific antisera. Neuropharmacology 24:1635–1645

    Article  Google Scholar 

  • Al-Janabi I, Arranz M, Blakemore A, Saiz P, Susce M, Glaser P, Clark D, de Leon J (2009) Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19:305–311

    Article  PubMed  Google Scholar 

  • Anderson I, Clark L, Elliott R, Kulkarni B, Williams S, Deakin J (2002) 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 13:1547–1551

    Article  PubMed  CAS  Google Scholar 

  • Bagdy G, Makara G (1995) Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. Eur J Pharmacol 275:301–305

    Article  PubMed  CAS  Google Scholar 

  • Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 324:1084–1092

    Article  PubMed  CAS  Google Scholar 

  • Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94–104

    PubMed  CAS  Google Scholar 

  • Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr (2002) Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 46:129–139

    Article  PubMed  CAS  Google Scholar 

  • Blackburn TP, Suzuki K, Ashby CR Jr (2006) The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 59:502–512

    Article  PubMed  CAS  Google Scholar 

  • Chagnon YC (2006) Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 7:1681–1695

    Article  PubMed  CAS  Google Scholar 

  • Clifton P, Lee M, Dourish C (2000) Similarities in the action of Ro 60-0175, a 5-HT2c receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152:256–267

    Article  PubMed  CAS  Google Scholar 

  • Damjanoska K, Muma N, Zhang Y, D’Souza D, Garcia F, Carrasco G, Kindel G, Haskins K, Shankaran M, Petersen B, Van De Kar L (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. J Pharmacol Exp Ther 304:1209–1216

    Article  PubMed  CAS  Google Scholar 

  • Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597

    Article  PubMed  Google Scholar 

  • Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53–61

    Article  PubMed  Google Scholar 

  • Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727–734

    Article  PubMed  Google Scholar 

  • Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998) Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37:265–272

    Article  PubMed  Google Scholar 

  • Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195–1205

    Article  PubMed  Google Scholar 

  • Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V (2003) RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 87:1402–1412

    Article  PubMed  CAS  Google Scholar 

  • Drago A, Serretti A (2009) Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet 150B:601–637

    Article  PubMed  CAS  Google Scholar 

  • Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862–869

    Article  PubMed  CAS  Google Scholar 

  • Egerton A, Ahmad R, Hirani E, Grasby P (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl) 200:487–496

    Article  CAS  Google Scholar 

  • Ellenbroek BA (2004) Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology (Berl) 174:65–74

    Article  CAS  Google Scholar 

  • Ellingrod V, Perry P, Lund B, Bever-Stille K, Fleming F, Holman T, Miller D (2002) 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 22:622–624

    Article  PubMed  CAS  Google Scholar 

  • Ellingrod V, Perry P, Ringold J (2005) Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 134:76–78

    Google Scholar 

  • Fletcher P, Tampakeras M, Sinyard J, Higgins G (2007) Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology 195:223–234

    Article  PubMed  CAS  Google Scholar 

  • Frank M, Stryker M, Tecott L (2002) Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropsychopharmacology 27:869–873

    Article  PubMed  CAS  Google Scholar 

  • Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221

    Article  PubMed  CAS  Google Scholar 

  • Gunes A, Dahl M-L, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64:477–482

    Article  PubMed  CAS  Google Scholar 

  • Gunes A, Scordo M, Jaanson P (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190:479–484

    Article  PubMed  CAS  Google Scholar 

  • Heisler LK, Chu HM, Tecott LH (1998) Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci 861:74–78

    Article  PubMed  CAS  Google Scholar 

  • Herrick-Davis K, Grinde E, Niswender CM (1999) Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 73:1711–1717

    Article  PubMed  CAS  Google Scholar 

  • Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226–232

    PubMed  CAS  Google Scholar 

  • Hill MJ, Reynolds GP (2007) 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 1149:14–17

    Article  PubMed  CAS  Google Scholar 

  • Hoffman B, Mezey E (1989) Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 247:453–462

    Article  PubMed  CAS  Google Scholar 

  • Ikram H, Samad N, Haleem DJ (2007) Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak J Pharm Sci 20:188–195

    PubMed  CAS  Google Scholar 

  • Kawahara Y, Grimberg A, Teegarden S, Mombereau C, Liu S, Bale T, Blendy J, Nishikura K (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28:12834–12844

    Article  PubMed  CAS  Google Scholar 

  • Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232–238

    Article  PubMed  CAS  Google Scholar 

  • Kostrzewa RM, Huang N-Y, Kostrzewa JP, Nowak P, Brus R (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11:41–50

    Article  PubMed  CAS  Google Scholar 

  • Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL (2010) HTS and rational drug design [RDD] to generate a class of 5-HT2C-selective ligands for possible use in schizophrenia. ChemMedChem 5:1221–1225

    Article  PubMed  CAS  Google Scholar 

  • Kuzman M, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H (2008) The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 160:308–315

    Article  PubMed  CAS  Google Scholar 

  • Lacivita E, Leopoldo M (2006) Selective agents for serotonin2C (5-HT2C) receptor. Curr Top Med Chem 6:1927–1970

    Article  PubMed  CAS  Google Scholar 

  • Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell’Osso L, Lucacchini A, Cassano GB (1999) Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 10:21–26

    Article  PubMed  CAS  Google Scholar 

  • Marquis KL, Dunlop J, Ramamoorthy S, Beyer CE, Lin Q, Brennan J, Piesla MJ, Ashby C, Harrison B, Magolda R, Pangalos MN, Stack G, Rosenzweig-Lipson S (2006) SCA-136: a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. Program No 934, Neuroscience Meeting Planner Atlanta, GA: Society for Neuroscience

    Google Scholar 

  • Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486–496

    Article  PubMed  CAS  Google Scholar 

  • Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924

    PubMed  CAS  Google Scholar 

  • Masellis M, Basile V, Meltzer H, Lieberman J, Sevy S, Macciardi F, Cola P, Howard A, Badri F, Nothen M, Kalow W, Kennedy JL (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19:123–132

    Article  PubMed  CAS  Google Scholar 

  • Mayers A, Baldwin D (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol Clin Exp 20:533–559

    Article  CAS  Google Scholar 

  • Meltzer H, Maes M (1995) Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry 385:310–318

    Article  Google Scholar 

  • Miller KJ (2005) Serotonin 5-HT2C receptor agonists: potential for the treatment of obesity. Mol Interv 5:282–291

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104

    Article  PubMed  CAS  Google Scholar 

  • Mombereau C, Kawahara Y, Gundersen B, Nishikura K, Blendy J (2010) Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology 59:468–473

    Article  PubMed  CAS  Google Scholar 

  • Morris E, Normandin M, Schiffer W (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol 10:67–73

    Article  PubMed  Google Scholar 

  • Morris E, Yoder K, Wang C, Normandin M, Zheng Q, Mock B, Muzic RJ, Froehlich J (2005) ntPET: a new application of PET imaging for characterizing the kinetics of endogenous neurotransmitter release. Mol Imaging 4:473–489

    PubMed  Google Scholar 

  • Müller D, Kennedy JL (2006) Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7:863–887

    Article  PubMed  Google Scholar 

  • Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M (2008) The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behav Brain Res 188:412–415

    Article  PubMed  CAS  Google Scholar 

  • Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274:9472–9478

    Article  PubMed  CAS  Google Scholar 

  • Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E (2001) RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 24:478–491

    Article  PubMed  CAS  Google Scholar 

  • Niswender CM, Sanders-Bush E, Emeson RB (1998) Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 861:38–48

    Article  PubMed  CAS  Google Scholar 

  • Nonogaki K, Strack A, Dallman M, Tecott L (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4:1152–1156

    Article  PubMed  CAS  Google Scholar 

  • Park Y, Cho J, Kang S, Choi J, Lee S, Kim L, Lee H (2008) Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 33:55–60

    Article  PubMed  Google Scholar 

  • Ramamoorthy P, Beyer C, Brennan J, Dunlop J, Gove S, Grauer S, Harrison BL, Lin Q, Malberg J, Marquis K, Mazandarani H, Piesla M, Pulicicchio C, Rosenzweig-Lipson S, Sabb A-M, Schechter L, Stack G, J Z (2006) Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of schizophrenia. 231st American Chemical Society National Meeting: MEDI-021

    Google Scholar 

  • Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83–89

    PubMed  CAS  Google Scholar 

  • Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572–574

    Article  PubMed  CAS  Google Scholar 

  • Reynolds G, Zhang Z, Zhang X (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086–2087

    Article  PubMed  CAS  Google Scholar 

  • Reynolds GP, Templeman LA, Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:1021–1028

    Article  PubMed  CAS  Google Scholar 

  • Rietschel M, Naber D, Finmmers R, Moller H, Propping P, Nothen M (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8:1999–2003

    Article  PubMed  CAS  Google Scholar 

  • Robinson ESJ, Dalley JW, Theobald DEH, Glennon JC, Pezze MA, Murphy ER, Robbins TW (2007) Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 33:2398–2406

    Article  PubMed  Google Scholar 

  • Rosenzweig-Lipson S, Beyer C, Hughes Z, Lin Q, Zhang M-Y, Grauer S, Comery T, Aschmies S, Stack G, Marquis K (2007a) Vabicaserin: Effects of a novel 5-HT2C agonist on prefrontal cortical neurotransmission, cognition and sensorimotor gating. European Neuropsychopharmacology The Journal of the European College of Neuropsychopharmacology 17(Supl.4):S484

    Google Scholar 

  • Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007b) Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-163909 in rodents. Psychopharmacology 192:159–170

    Article  PubMed  CAS  Google Scholar 

  • Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J (2006) Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res 1073–1074:240–251

    Article  PubMed  Google Scholar 

  • Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, Harrison B (2004) Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett 14:2603–2607

    Article  PubMed  CAS  Google Scholar 

  • Sargent P, Sharpley A, Williams C, Goodall E, Cowen P (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309–312

    Article  PubMed  CAS  Google Scholar 

  • Segman R, Heresco-Levy U, Finkel B (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 152:408–413

    Article  PubMed  CAS  Google Scholar 

  • Sharpley A, Soloman R, Fernando A, da Roza DJ, Cowen P (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology (Berl) 101(4):568–569

    Article  CAS  Google Scholar 

  • Sharpley A, Vassaollo C, Cowen P (2000) Olanzapine increases slow-eave sleep; evidence for blockade of central 5-HT2c receptors in vivo. Biol Psychiatry 47:468–470

    Article  PubMed  CAS  Google Scholar 

  • Shen et al. (2011) Neuropsychopharmacology 36:S75–S197. doi:10.1038/npp.2011.291

  • Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT2C receptor antagonist. Neuropsychopharmacology 30:372–380

    Article  PubMed  CAS  Google Scholar 

  • Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT(2C) agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279–290

    Article  PubMed  CAS  Google Scholar 

  • Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ (2001) RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6:373–379

    Article  PubMed  CAS  Google Scholar 

  • Stark J, McKie S, Davies K, Williams S, Luckman S (2008) 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur J Neurosci 27:457–465

    Article  PubMed  Google Scholar 

  • Tecott L, Sun L, Akana S, Strack A, Lowenstein D, Dallman M, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542–546

    Article  PubMed  CAS  Google Scholar 

  • Templeman L, Reynolds G, Arranz B, San L (2005) Polymorphisms of the 5HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195–200

    Article  PubMed  CAS  Google Scholar 

  • Tsuno N, Besset A, Ritchie K (2005) Sleep and depression. J Clin Psychiatry 66:1254–1269

    Article  PubMed  Google Scholar 

  • Winstanley CA, Theobald DEH, Dalley JW, Glennon JC, Robbins TW (2004) 5-HT 2A and 5-HT 2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology 176:376–385

    Article  PubMed  CAS  Google Scholar 

  • Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN (2006) Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 5:445–452

    Article  PubMed  CAS  Google Scholar 

  • Yevtushenko O, Cooper S, O’Neill R, Doherty J, Woodside J, Reynolds G (2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192:424–428

    Article  PubMed  Google Scholar 

  • Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521–529

    Article  PubMed  CAS  Google Scholar 

  • Zhang Z, Zhang X, Sha W (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670–671

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroscience, Pfizer Worldwide Research and Development, Groton, CT, USA

    Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross & John Dunlop

  2. IVS Pharma Consulting, LLC, 8 Stage Coach Run, East Brunswick, NJ, 08816, USA

    Sharon Rosenzweig-Lipson

  3. Neuroscience iMed, Astra Zeneca, Cambridge, MA, 02142, UK

    John Dunlop

Authors
  1. Sharon Rosenzweig-Lipson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Comery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen L. Marquis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John Dunlop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharon Rosenzweig-Lipson .

Editor information

Editors and Affiliations

  1. Dept. Psychiatry, University of California San Diego, Gilman Drive 9500, La Jolla, 92093-0804, California, USA

    Mark A. Geyer

  2. Institut für Pharmakologie, Universität, Neuroscience Research, Abbott GmbH & Co. KG, Knollstraße, Ludwigshafen, 67061, Germany

    Gerhard Gross

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rosenzweig-Lipson, S., Comery, T.A., Marquis, K.L., Gross, J., Dunlop, J. (2012). 5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia. In: Geyer, M., Gross, G. (eds) Novel Antischizophrenia Treatments. Handbook of Experimental Pharmacology, vol 213. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25758-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation